

Johnson&Johnson

Featured data at AAN 2026



American Academy of Neurology Annual Meeting

Chicago, Illinois
April 18 - April 22, 2026

Johnson & Johnson sponsored studies		
Poster Number	Title	Presentation Time
EFFICACY AND SAFETY		
Vivacity-MG3: Open-Label Extension: 2 Year Follow-Up		
#9-019	Long-term Safety and Efficacy of Nipocalimab: Approximately Two Years Follow-up Results From the Open-label Extension Phase of Vivacity-MG3 Study	Tuesday, April 21 5:00 PM-6:00 PM CT
Vivacity-MG3: IgG Reduction and MG-ADL Improvement		
#9-006	Assessing the Relationship Between Immunoglobulin G Level and Efficacy of Nipocalimab Measured Using Myasthenia Gravis-activities of Daily Living scale	Monday, April 20 8:00 AM-9:00 AM CT
Vivacity-MG3: Sustained Minimal Symptom Expression		
#9-007	Quality of Life in Patients With Generalized Myasthenia Gravis Achieving Sustained Versus Transient Minimal Symptom Expression in the Phase Three Vivacity-MG3 Trial	Tuesday, April 21 5:00 PM-6:00 PM CT
REAL WORLD EVIDENCE & PATIENT EXPERIENCE		
Mortality in MG Medicare Population		
#9-018	Differences in Mortality Among Medicare Beneficiaries With and Without Generalized Myasthenia Gravis	Monday, April 20 8:00 AM-9:00 AM CT
Healthcare Costs in Pediatric MG		
#8-001	Healthcare Costs in Commercially Insured Pediatric Patients with Generalized Myasthenia Gravis in the United States	Tuesday, April 21 11:45 AM-12:45 PM CT
Pediatric MG Clinical Events Risk Factors		
#8-002	Factors Associated with Recurrent Clinical Events among Pediatric Generalized Myasthenia Gravis Patients in the United States	Tuesday, April 21 11:45 AM-12:45 PM CT
ADELPHI Disease Specific Programs		
#9-008	Self-reported Clinical Characteristics of a U.S. Generalized Myasthenia Gravis Population Treated With Standard of Care Therapy: Results From a Real-world Patient Survey	Wednesday, April 22 11:45 AM-12:45 PM CT